However, a significantly lower percentage of CD38+ cells among CD45RA− CXCR5+ Tfr found in our patients with CLL compared to HC could impact plasmablast differentiation and the associated early antibody response [51,52]. This evidence concerns the gene TFRC and B-cell chronic lymphocytic leukemia.